The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry - WMBB News 13 - The Panhandle's News Leader

The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

  • What's Going AroundMore>>

  • What's Going Around - April 16th

    What's Going Around - April 16th

    Wednesday, April 16 2014 11:16 AM EDT2014-04-16 15:16:33 GMT
    Sinus infections are going around this week. Nurse Practitioner Christy Johnson from Bay Medical-Sacred Heart Family Medicine says, "A sinus infection is inflammation or swelling of your sinuses. WhenMore >>
    A sinus infection can make a person feel miserable. More >>
  • Jessica Foster

    Jessica Foster

    Jessica Foster is originally from Atlanta, Georgia and has worked at WMBB since 2004. She is excited to bring the news to you each weekday on News13 This Morning. Jessica produces 3 medical segments weekly- What's Going Around, Modern Medicine and Mayo Clinic reports.More >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Research and Markets

DUBLIN, Apr. 03, 2014 /PRNewswire/ --

Research and Markets

(

http://www.researchandmarkets.com/research/gw6znv/the_engineered

) has announced the addition of the

"The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry"

report to their offering.



(Logo:http://photos.prnewswire.com/prnh/20130307/600769)

A Comparative Analysis And Assessment Of TCR Technologies, Pipelines And Companies From An Industry Perspective



Therapeutic monoclonal antibodies have become an increasingly successful treatment modality with sales of US$ 65 bln in the year 2012 and with an average (continuous) annual growth rate from 2006 to 2012 of 18.9%. While antibody technologies are steadily evolving, the spectrum of druggable targets for monoclonal antibodies has remained limited to extracellular antigens, albeit including proteins, carbohydrates and glycolipids.



Access to druggable, IP-protected and validated new targets is a major bottleneck in the biopharmaceutical industry. Technologies which can deliver both new targets and the corresponding treatment modality, can expect significant financial acknowledgement.



The T-cell receptor (TCR) has recently emerged as a means to target peptide antigens derived from intracellular proteins, however, in a major histocompatibility complex (MHC)-restricted manner. The first companies have overcome significant technical hurdles in putting together a library of viable new TCR-targeted antigens and establish the corresponding standardized protein- and cell-based therapeutic frameworks.



This report entitled 'The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry' describes chances and pitfalls in exploiting the opportunities which offers the engineered T-cell receptor as integral part of fusion proteins, antibodies and cellular products. The key success factors are highlighted, the technical challenges described and solutions presented.



Benefits from the report:

  • Identify players in the field, from industry and academia;
  • Find out which TCR technologies are valued by Big Pharma and Biotech;
  • Understand the value of intracellular antigens targeted by the TCR;
  • Recognize the challenges of TCR-based therapeutics and their solutions;
  • Learn which TCR-based therapeutics are attractive for partnering;
  • Find out which TCR therapeutic approaches are not yet tapped.


Key Topics Covered:

1. Executive Summary

2. Introduction

3. The T-Cell Receptor

4. TCR Fusion Proteins

5. TCR-Like (TCRL) Antibodies

6. TCR-Transfected T-Cells

7. Artificial TCR T-Cells: Chimeric Antigen Receptor (CAR) T-Cells

8. Tumor-Infiltrating Lymphocytes (TILs)

9. Opportunity Analysis for TCR-based Products and Technologies

10. References

11. Corporate R&D Pipelines


Companies Mentioned:

  • Adaptimmune
  • Altor Bioscience
  • Immunocore
  • Lion Biotechnologies


For more information visit http://www.researchandmarkets.com/research/gw6znv/the_engineered


Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net



 

©2012 PR Newswire. All Rights Reserved.